We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Serological Assays Define Extent of Legionnaires’ Disease Outbreak

By LabMedica International staff writers
Posted on 29 Apr 2015
Microbiological diagnosis of Legionnaires’ disease (LD) during acute illness is based on culture, polymerase chain reaction (PCR) of respiratory samples, and/or detection of Legionella antigen in urine. More...


The isolation of Legionella spp. by culture is considered the gold standard for diagnosing LD, but the sensitivity is low, and the urinary antigen test (UAT) has become the most performed test in diagnosing LD because of its easy performance and rapidity.

Scientists at the Ostfold Hospital Trust (Sarpsborg, Norway) investigated a long-distance outbreak of LD caused by Legionella pneumophila serogroup 1 that occurred in south-east Norway. The initial outbreak investigation without serology identified 56 laboratory-confirmed LD cases of whom 10 died. However, 116 patients with community-acquired pneumonia (CAP) might belong to the outbreak based on epidemiological investigations, but acute laboratory tests other than serology were negative or not performed.

To assess the true extent of the outbreak, they evaluated two serological assays in order to reclassify the 116 patients with indeterminate case status. The two commercial polyvalent serological L. pneumophila assays were used for evaluation of the methods and the outbreak investigation: a serogroup 1–6 immunoglobulin (Ig) G/IgM/IgA immunofluorescence assay (IFA) (Meridian Bioscience Europe; Milan, Italy) and a serogroup 1–7 enzyme-linked immunosorbent assay (ELISA) (Serion ELISA classic, Institut Virion/Serion GmbH; Würzburg, Germany) with separate levels of IgG and IgM antibodies measured in an ELISA robot (DSX Automated System, Dynex Technologies; Inc., Chantilly, VA, USA). Antibodies to the outbreak strain were determined by immunoblotting.

In the evaluation study, the sensitivity and specificity of an equal to or greater than four-fold IFA titre change was 38% and 100%, respectively, with corresponding values of 30% and 99% for seroconversion in ELISA. A single high positive IFA titre yielded sensitivity and specificity of 73% and 97%, respectively, with corresponding values of 68% and 96% for a single high immunoglobulin (Ig) G and/or IgM in ELISA.

The serological testing identified 47 more LD cases, and the outbreak thus comprised 103 cases with a case fatality rate of 10%. About the same proportion (70%) of the urinary antigen positive and negative LD cases had antibodies to the serogroup-specific lipopolysaccharide of the outbreak strain. In addition to the 103 LD cases, Legionella infection could not be verified or excluded in 32 patients based on epidemiology and/or lack of microbiological sampling.

The authors concluded that the acute-phase tests including culture, polymerase chain reaction, and urinary antigen identified less than 55% of the 103 patients in this outbreak. Serological testing thus remains an important supplement for diagnosis of LD and for determination of outbreak cases. The study was published on March 28, 2015, in the journal BMC Infectious Diseases.

Related Links:

Ostfold Hospital Trust
Meridian Bioscience Europe 
Dynex Technologies 



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.